{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "9a0d11490684f8051d7e8324910d5965",
    "title": "Innovent",
    "source_uri": "2025-08-29/Rapid growth with global expansion story reiterate Buy and lift PO to HK106.9Rapid growth with global expansion story re_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:01:06.204431",
      "extracted_at": "2025-10-27T00:01:06.204437"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 12,
        "successful_pages": 12,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 3,
          "reduction_ratio": 0.18566022108980484
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "7b7ce1f0cf34c40c",
      "text": "Reiterate Rating: BUY | PO: 106.90 HKD | Price: 90.65 HKD",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "47404970480cfebc",
      "text": "In 1H25, Innovent registered total revenue/product revenue of RMB6.0bn/5.2bn, implying YoY growth of \\(50.6\\% /37.3\\%\\) . Its GPM improved to \\(86.0\\%\\) in 1H25, up 3.1ppt vs. 1H24. After excluding license and R&D service income, the GPM was \\(84\\%\\) vs. \\(82\\%\\) in 1H24. On the open front, R&D expense fell \\(27.9\\%\\) YoY to RMB1.0bn; further, thanks to enhanced efficiency, S&M expense was RMB2.4bn, accounting for \\(45.4\\%\\) product revenue (49.3% in 1H24). Overall, Innovent achieved a net profit of RMB834mn, vs net loss of RMB393mn in 1H24. After excluding the impact from SBC and net foreign exchange change, the adjusted net profit reached RMB1,213mn (net loss of RMB160mn in 1H24).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dc6cb73793d7bfb2",
      "text": "This week, we note US FDA has cleared the IND application to initiate a global Phase III trial of IB1363. Innovent plans to kick off the trial in 2H25. To reflect its pipeline progress, we add IB1363's POS adjusted overseas revenue from 2028E into our model. We lift PoS for IB1363 indications in China considering its smooth progress and lift PoS to \\(100\\%\\) for taletrectinib and mazutide obesity indication, given these drugs were approved in 1H25. We also lift peak sales forecast for sintilimab amid its continuous market share gains. We hike 2025E- 26E GPM by 0.6- 0.8ppt considering its improved efficiency. We also update the observed beta to 0.8 from 0.85 and WACC to \\(9.6\\%\\) from \\(10\\%\\) . Driven by raised peak sales forecast, we lift DCF- derived PO to HK\\$106.9 (from HK\\$70.1) and reiterate Buy given its solid R&D capability and rich pipeline portfolio.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7930bc58f6fe6b91",
      "text": "In 1H25, Innovent launched five new products, including its CVM cornerstone product Mazutide, DOVBLERON (taletrectinib), limertinib (EGFR TKI), Jaypirca (piribotrubinit) and SYCUME (petrotrumumab). Moreover, it has licensed- out IB13009 (DLL3 ADC) to Roche and received US\\$80mn in upfront payments. Near- term catalysts for Innovent include, 1) new products approval: autoimmune cornerstone asset of IB1112 (picankibart, IL- 23p19) and IB1310 (ipilimumab NO1, CTLA- 4) around YE25; and 2) pipeline advancement and data readouts: initiate first global ph3 studies for IB1363 (PD- 1/IL- 2) and PoC readout in 2026, as well as mazutide DREAMs- 3 (vs. semaglutide) ph3 data readout in 2H25.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bffeaa624ebafba7",
      "text": "Estimates (Dec) (CNY)2023A2024A2025E2026E2027ENet Income (Adjusted - mn)(1,028)(95)5451,3822,864EPS(0.670)(0.058)0.3350.8491.76EPS Change (YoY)54.2%91.3%NM153.6%107.3%Consensus EPS (Visible Alpha)0.390.651.38Free Cash Flow / Share(1.04)(0.996)0.1990.4261.21Valuation (Dec)P/ENMNM249.02x98.20x47.36xEV / EBITDA*NM389.13x90.52x51.63x30.53xFree Cash Flow Yield-1.18%-1.20%0.239%0.511%1.46%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "830832683a4a9bad",
      "text": "\\\\* For full definition of Method\\\\* measures, see page 9.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bf3dda30228bfa07",
      "text": ">> Employed by a non- US affiliate of BoFAS and is not registered/qualified as a research analyst under the FINRA rules.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "431d9f6704489f67",
      "text": "Refer to \"Other Important Disclosures\" for information on certain BoFA Securities entities that take responsibility for the information herein in particular jurisdictions.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "698e4e588d05a6ed",
      "text": "BoFA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2f6f21fb6434c814",
      "text": "Refer to important disclosures on page 10 to 12. Analyst Certification on page 7. Price Objective Basis/Risk on page 7. 12870851",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7e08bad4f767af3c",
      "text": "Key Changes(CNY)Previous CurrentPrice Obj.HK$70.10 HK$106.90",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "011edf3946748a14",
      "text": "Stock DataPrice90.65 HKDPrice Objective106.90 HKDDate Established28-Aug-2025Investment OpinionC-1.952-Week Range28.65 HKD-106.00 HKDMkt Val / Shares Out (mn)18,943 USD / 1,627.5Market Value (mn)147,529 HKDAverage Daily Value (mn)254.95 USDFree Float82.8%BoFA Ticker / ExchangeIVBXF / HKGBloomberg / Reuters1801 HK / 1801 HKROE (2025E)4.1%Net Dbt to Equity (Dec-2024A)-35.8%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fa002e13b8622ef2",
      "text": "SBC: share based compensation PoS: probability of success CVM: cardiovascular and metabolism EGFR TKI: epidermal growth factor receptor tyrosine kinase inhibitor DLL3: delta- like ligand 3 ADC: Antibody- Drug Conjugate CTLA- 4: anti- cytotoxic T lymphocyte antigen 4 PD- 1/IL2: programmed cell death protein 1/Interleukin 2 PoC: proof- of- concept FDA: Food and Drug Administration IND: investigational new drug See other abbreviations in page 6.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d452a49d3a26ce81",
      "text": "Key Income Statement Data (Dec)2023A2024A2025E2026E2027E(CNY Millions)Sales6,2069,42212,10915,98821,250Gross Profit5,0707,9129,95313,09017,548Sell General &amp;amp; Admin Expense(3,851)(5,085)(5,715)(7,355)(8,925)Operating Profit(1,009)1461,2712,3784,161Net Interest &amp;amp; Other Income(99)(109)(53)(99)(69)AssociatesNANANANANAPretax Income(1,107)371,2182,2794,092Tax (expense) / Benefit116(16)(81)(206)(428)Net Income (Adjusted)(1,028)(95)5451,3822,864Average Fully Diluted Shares Outstanding1,5351,6271,6271,6271,627",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9c84575598597483",
      "text": "Key Cash Flow Statement Data",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fcc388b8c4cb3d4e",
      "text": "Net Income(991)211,1362,0723,664Depreciation &amp;amp; Amortization187196196193188Change in Working Capital77(47)(363)(511)(615)Deferred Taxation ChargeNANANANANAOther Adjustments, Net(563)(1,508)(403)(822)(944)Cash Flow from Operations(1,290)(1,339)5669332,293Capital Expenditure(310)(283)(242)(240)(319)(Acquisition) / Disposal of InvestmentsNANANANANAOther Cash Inflow / (Outflow)00000Cash Flow from Investing(310)(283)(242)(240)(319)Shares Issue / (Repurchase)00000Cost of Dividends PaidNANANANANACash Flow from Financing2,489(922)NA5000Free Cash Flow(1,600)(1,621)3246931,974Net Debt(6,530)(4,691)(5,014)(5,707)(7,682)Change in Net Debt(471)3,044500(693)(1,974)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3881c10162c05a3d",
      "text": "Key Balance Sheet Data",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f63fb7abb0be2edf",
      "text": "Property, Plant &amp;amp; Equipment4,2905,2805,3265,3735,503Other Non-Current Assets2,9106,0506,6557,3218,053Trade Receivables1,0061,1841,2771,5992,008Cash &amp;amp; Equivalents10,0527,5087,6948,88810,862Other Current Assets2,3701,5802,3272,8603,439Total Assets20,62721,60323,28026,04029,866Long-Term Debt2,3272,4122,1442,5442,544Other Non-Current Liabilities1,2961,7042,1212,3332,566Short-Term Debt1,195405536636636Other Current Liabilities3,2823,9644,8165,4826,211Total Liabilities8,1008,4859,61710,99611,958Total Equity12,52813,11813,66215,04417,908Total Equity &amp;amp; Liabilities20,62721,60323,28026,04029,866",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4b8d9d892559cc25",
      "text": "iQmethod™ - Bus Performance*Return On Capital Employed-5.6%0.5%6.3%11.0%16.9%Return On Equity-8.8%-0.7%4.1%9.6%17.4%Operating Margin-16.3%1.5%10.5%14.9%19.6%EBITDA Margin-13.2%3.6%12.1%16.1%20.5%iQmethod™ - Quality of EarningsCash Realization RatioNMNM1.0x0.7x0.8xAsset Replacement Ratio1.7x1.4x1.2x1.2x1.7xTax Rate (Reported)10.5%43.3%6.7%9.1%10.5%Net Debt-to-Equity Ratio-52.1%-35.8%-36.7%-37.9%-42.9%Interest Cover-10.2x2.2x7.3x9.2x14.8x",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "348fdf4be3e2a7a5",
      "text": "Key Metrics\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\*\\\\* For full definitions of iQmethodTM measures, see page 9.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "35c0936b22f98580",
      "text": "\\\\* For full definitions of iQmethodTM measures, see page 9.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8a0365f2c3f55201",
      "text": "Innovent Biologics is a commercial- stage biopharmaceutical company in China. Innovent develops, manufactures, and distributes biologics drugs mainly for the treatment of oncology. Other disease areas that Innovent is working on include ophthalmology, autoimmune, and cardiovascular diseases. It currently markets PD- 1 drug sintilimab in China, which is co- developed with Eli Lilly.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4158ea4013a36baf",
      "text": "Our Buy rating is based on the following: 1) As the first PD- 1 in the National Reimbursement Drug List (NRDL), we estimate that sintilimab China peak sales could reach RMB 2bn or more. 2) Three biosimilar drugs are cash cows, that continuously contributing cash for R&D. 3) The rich biologic pipeline could provide sustainable growth. Its pipeline includes monoclonal antibodies, bispecific antibodies, CAR- T, small molecules and peptide.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cb2b3c8d16ef033a",
      "text": "Exhibit 1: We lift 2025E-27E revenue estimate by \\(1 - 2\\%\\) and raise long-term revenue forecast given pipeline progress We lift 25E-26E GPM estimate by 0.6-0.8ppt, given improved efficiency",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a397c5de14a8cc91",
      "text": "NewOld% Change (New vs Old)2025E2026E2027E2025E2026E2027E2025E2027ETotal Revenue12,10015,98821,25011,90515,75321,0072%1%1%COGS-2,150-2,898-3,701-2,220-2,947-3,661-3%-2%1%Gross profit9,95313,09017,5489,68512,80617,3473%2%1%R&amp;amp;D expense-3,358-4,462-2,917-3,308-4,4122%1%1%1%SG&amp;amp;A expense-7,715-7,355-8,925-5,619-7,246-8,8232%1%1%Other income/expense400400400400400400Operating income6791,6873,3617381,7593,530-8%-4%-5%Other income/expenses1211602121191582102%1%1%Finance costs-174-259-281-174-259-2810%0%0%Profit Before Tax6261,5883,2926831,6573,459-8%-4%-5%Tax expense-81-206-428-89-215-450-8%-4%-5%Net Income5451,3822,8645951,4423,009-8%-4%-5%Basic EPS0.330.851.760.370.891.85-8%-4%-5%Fully diluted EPS0.330.851.760.370.891.85-8%-4%-5%(changes in percentage points)Gross margin (%)82%82%83%81%81%83%0.80.60.0R&amp;amp;D expense % of sales-25%-21%-21%-25%-21%-21%0.00.00.0SG&amp;amp;A % of sales-47%-46%-42%-47%-46%-42%0.00.00.0Operating margin (%)6%11%16%6%11%17%-0.6-0.6-1.0Tax rate (%)-13%-13%-13%-13%-13-13%0.00.00.0Net margin (%)4%9%13%5%9%14%-0.5-0.5-0.8% yoyRevenue29%32%33%26%32%33%2.2-0.3-0.5",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5c536ba98e7936fe",
      "text": "Source: BofA Global Research Estimates.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "39a4bda71357b7c2",
      "text": "To reflect its pipeline progress, especially Innovent's plan to initiate its global ph3 trial for IBI363 in 2H25, we add IBI363 overseas revenue forecast from 2028E into our model. We lift PoS to \\(70\\%\\) from \\(40\\%\\) for IBI363 indications in China considering its smooth progress. We also lift PoS to \\(100\\%\\) for taletrectinib and mazdutide obesity indication given these drugs were approved in 1H25. We raise peak sales forecast for sintilimab given its continuous market share gain. We also update license income to RMB666mn (from RMB584mn) based on the number announced in 1H25 results. We also update observed beta to 0.8 from 0.85 based on Bloomberg (1- yr) and WACC to \\(9.6\\%\\) from \\(10\\%\\) , while other DCF assumptions remain unchanged. Driven by significantly raised long- term sales forecast, we lift DCF- derived PO to HK\\$106.9 (from HK\\$70.1).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6f7ea5d6b1cf719b",
      "text": "Exhibit 2: Add IBI363 overseas revenue forecast and lift PoS for key assets",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5ff62b17386c4561",
      "text": "OldNewNew Year of Peak Sales (RMBmn)Adjusted Peak SalesOld Year of Peak (RMBmn)SalesNew PoSAdjusted Peak SalesNew Peak SalesAssetIndicationOld PoSNANA40%12,5032033EIBI363-overseasNSCLCNANA2033E70%2,7202033EIBI363-ChinaNSCLC40%1,5542033E70%3932032EMelanoma40%2242032E70%1,0692033ECRC40%6112033E70%4,4682034ESintilimab//4,3082027E/2952032EDOVBLERON (taletrectinib)ROS1+ NSCLC95%2802032E100%6,4642029EMazdutideObesity95%6,1412029E100%",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b75a0c110303ffeb",
      "text": "Source: BofA Global Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c7c4c66754ef3287",
      "text": "For key oncology pipelines, Innovent will initiate the first global ph3 trial of its potential first-in-class IBI363 (PD-1/IL-2 α-bias) in IO-resistant sqNSCLC in 2H25. It aims to recruit c.600 patients globally, including China, the US, Canada, the EU, the UK and Japan, etc. The primary endpoint for this trial is overall survival. In addition, PoC data readouts for IBI363 in 1L NSCLC and 1L MSS CRC is anticipated in 2026. Regarding IBI343 (CLDN18.2 ADC), Innovent has initiated ph3 trial in 3L+ PDAC in Aug 2025 and is planning global ph3 trial in 2L+ PDAC, which is subject to regulatory approval. With respect to general biomedicine pipelines, Innovent is expected to provide data readouts for GLORY-2 ph3 study and DREAMS-3 (vs. semaglutide) ph3 study in 2H25. Overall,Innovent reiterated its target of RMB20bn product revenue with 20 commercial products in 2027 and aims to have over five pipeline assets in global MRCT phase 3 trial in 2030.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a040e80e29c54b18",
      "text": "Regarding global collaborations, Innovent has entered an exclusive license agreement with Roche for the global rights of IBI3009 (DLL3 ADC) in Jan 2025. Under the agreement, Innovent and Roche will jointly focus on the early-stage development of IBI3009, after which Roche will take over the full development. Innovent has received US&#36;80mn upfront in 1H25 and is eligible to receive up to US&#36;1bn in development and commercial milestone payments, as well as tiered royalties on net sales.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6f26a6d0f7a94b72",
      "text": "Exhibit 4: Innovent launched 5 new products in 1H25 and expect to receive approvals for two new drugs and three new indications in 2H25",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7e0914495bed590b",
      "text": "New products approval includes its autoimmune cornerstone asset of IBI112 (picanikbart, IL-23p19) and IBI310 (ipilimumab N01, CTLA-4) around YE25.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3bd9359ecb36144e",
      "text": "ProductTargetIndicationLaunched in 1H25DOVBLERON (taletrectinib)ROS11L ROS1+ NSCLC; 2L ROS1+ NSCLCLimeritibEGFR1L EGFR 19DEL/L858R NSCLC; 2L EGFR T790M+ NSCLCJapirica (pirtobrutinib)BTKMCLSYCUME (tepotrumumab N01 injection)IGF-1RTEDMazdutideGCG/GLP-1 Obesity (4/6mg)New drug approval in 2H25IBI112 (picanikbart)IL-23p19Moderate-to-severe plaque psoriasisIBI310 (ipilimumab N01 injection)CTLA-4Combination with sintilimab as neoadjuvant therapy for MSI-H/dMMR colon cancerNew indications approval in 2H25TYYYT (sintilimab)PD-12L of RCCNeoadjuvant therapy for MSI-H/dMMR colon cancerMazdutideGCG/GLP-1 T2D",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c5c4c987b8653255",
      "text": "Source: BofA Global Research, Innovent",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9b915d5307fa7566",
      "text": "BofA GLOBAL RESEARCH",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cfac515578fbfce8",
      "text": "Exhibit 5: Key R&D development for its rich oncology and general biomedicine pipelines",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cbb969bc2a72771e",
      "text": "Key highlights include to initiate IBI363 IO-resistant sqNSCLC global ph3 trial in 2H25; mazdutide DREAMS-3 ph3 and GLORY-2 ph3 data readout in 2H25.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4e91439b3cf1cb9e",
      "text": "Pipeline OncologyTargetIndicationMajor development progressTYYYTPD-1Neoadj. Colon Cancer2L RCCPerioperative NSCLCNDA in reviewNDA in reviewPh3 ongoingIBI310CTLA4Neoadj. Colon CancerNDA in reviewIBI354HER2 ADCPROCPh3 ongoingIBI363PD-1/IL-2 α-biasIO-naive MelanomaIO-resistant sqNSCLC3L+ MSS CRCEGFRm, PROC and morePivotal Ph2 since in 25H1Global Ph3 in 25H2Ph3 in planPoC ongoingPoC ongoing; PoC readout in 2026PoC ongoing; PoC readout in 2026IBI343CLDN18.2 ADC1L NSCLCNon-AGA nsqNSCLC Neoadjuvant3L+ GC3L+ PDAC2L+ PDACPh3 ongoingPh3 ongoingPh3 ongoingPh3 preparation in 25H2",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "652cf24144c86119",
      "text": "Key highlights include to initiate IBI363 IO-resistant sqNSCLC global ph3 trial in 2H25; mazdutide DREAMS-3 ph3 and GLORY-2 ph3 data readout in 2H25.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "85fddd10269f5b5f",
      "text": "PipelineTargetIndicationMajor development progressIBI3001IBI3003IBI3020EGFR/B7H3 ADCGPRC5D/BCMA/CD3CEACAM5 dp ADC1L PDACPh1b ongoingSolid tumorsPh1 ongoingMMPh1 ongoingGeneral biomedicineSolid tumorsPh1 ongoingSYCUMEIGF-1RInactive TEDPh3 in Plan in 25H2H2H Steroid Therapy in TEDPh3 in Plan in 25H2MazdutideGCG/GLP-1T2DNDA in reviewDREAMS-3 T2D w. obesity vs. SemaPh3 readout in 25H2GLORY-2 Moderate-to-severe obesityPh3 readout in 25H2 GLORY-Young Adolescent obesityPh3 to initiate in 25H2PicanikbartIL-23p19PsoriasisNDA in reviewTigulixostatXO1Hyperuricemia in GoutPh3 to initiate in 25H2IBI356OX40LADPh2 to initiate in 25H2IBI355CD40LpSSPh1 ongoingIBI3002TSLP/IL-4RαAsthmaPh1 ongoingIBI3032GLP-1 oralObesity & DiabetesPh1 to initiate in 25H2",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e6e51bdfc73b5c9a",
      "text": "Source: BofA Global Research, Innovent",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "36b74522a5875df7",
      "text": "According to IQVIA sample drug sales data, in Jun 2025, Innovent booked total sample sales of RMB549.8mn, representing a 53.1% YoY growth. Its key drugs sintilimab and bevacizumab posted robust growth of 66.5% and 42.8% YoY in Jun. Also thanks to the inclusion of NRDL, its tafolecimab registered RMB21.7mn sample sales in Jun 2025,compared with RMB1.6mn in Jun 2024. Overall, in 1H25, Innovent's sample drug sales data witnessed 35.8% YoY growth, largely in line with its announced product sales growth of 37.3% in 1H25.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "652534d53ec4e7ab",
      "text": "Exhibit 6: Innovent's Jun 2025 IQVIA monthly drug sales up 53.1% YoY, or 35.8% YoY in 1H25",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3209db76fceca972",
      "text": "One of its key drugs, sintilimab booked RMB257.8mn sales in Jun-25, representing a 66.5% YoY increase. Other key drugs that we monitor posted YoY growth change range from -4.2% to +1289.0% in Jun-25.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3c29e55e7239538b",
      "text": "RMB mnJun-25May-25Apr-25Mar-25Feb-25Jan-25Dec-24Nov-24Oct-24Sep-24Aug-24Jul-24SINTILIMAB257.8231.8246.8228.6179.2267.5217.1223.2182.9225.8186.7172.2YoY66.5%13.8%31.3%44.9%47.6%46.6%58.6%55.3%71.9%22.1%15.9%16.2%BEVACIZUMAB176.7171.0171.4154.0114.2179.7135.2145.0147.3174.7153.1143.1YoY42.8%2.6%36.2%51.3%32.3%64.5%11.0%23.9%106.0%57.6%54.6%62.2%RITUXIMAB67.165.271.862.551.582.362.657.457.673.965.959.5YoY14.2%-3.2%15.6%13.2%15.4%19.0%41.3%18.0%48.9%28.3%39.7%49.4%TAFOLECIMAB21.717.111.03.12.72.61.51.91.61.51.51.4YoY1289.0%1503.1%1053.8%165.0%213.0%277.5%-23.4%3053.7%189.0%203.7%NANAADALIMUMAB6.36.26.26.34.06.76.85.85.67.26.07.1YoY-4.2%6.8%-8.9%10.4%0.5%7.0%29.2%17.9%27.1%16.0%55.1%95.8%OLVEREMBATINIB8.46.15.98.12.86.76.75.24.86.72.65.7YoY52.0%83.9%65.6%140.2%4.7%102.9%87.2%85.8%63.6%68.3%2.2%99.4%SELPERCATINIB4.43.73.75.33.45.65.43.93.74.24.33.6YoY14.5%10.5%20.2%82.5%53.2%44.1%151.6%124.6%207.9%96.1%134.2%242.1%RAMUCIRUMAB2.12.22.31.81.62.42.12.21.61.51.71.9YoY11.1%22.1%-1.5%-15.4%2.8%13.6%18.7%31.0%-6.6%-9.5%1.6%-8.0%TEPROTUMUMAB3.01.30.40.00.00.00.00. 00.00.00.00 .0YoYNANANANANANANA NANANANANA",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "43753b687d315b92",
      "text": "Source: BofA Global Research, IQIVA",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "80010165316bfef3",
      "text": "China PD- 1/L- 1 competition landscape: BeOne's tislelizumab maintained No.1, followed by Innovent's sintilimab ranked No.2 and Merck's pembrolizumab remained No.3 from Jun- 24 to Jun- 25.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6629a77744002470",
      "text": "Source: BofA Global Research, IQIVA",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ed3f29dbecb9210c",
      "text": "China bevacizumab competition landscape: Qilu Pharma remained No.1 but gradually lose market share in the past one year; while Innovent maintained No.2 with market share reached the highest in Jun- 25 during the past one year.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1052c26e9a76f702",
      "text": "Source: BofA Global Research, IQIVA",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0fd1e31888f5da6d",
      "text": "Abbreviation summary as below",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d1fe1edb3e1c8d4b",
      "text": "AbbreviationADatopic dermatitisMSI-H/dMMRmicrosatellite instability-high or mismatch repair-deficientADCAntibody-Drug ConjugateMSSmelanoma and microsatellite stableBCMAB cell maturation antigenNDANew drug applicationBTKBruton&#x27;s tyrosine kinaseNSCLCNon-small cell lung cancerCD40LCD40 ligandOX40LOX40 ligandCEACAM5 dpcarcinoembryonic antigen-related cell adhesion molecule type 5PD-1/IL-2programmed cell death protein 1/Interleukin 2CLDN18.2Claudin18.2PDACpancreatic ductal adenocarcinomaCRCcolorectal cancerPD-L1Programmed cell death protein ligand 1CTLA-4anti-cytotoxic T lymphocyte antigen 4POCproof-of-conceptCVMcardiovascular and metabolismPoSProbability of successDLL3delta-like ligand 3PROCplatinum-resistant ovarian cancerEGFRepidermal growth factor receptorpSSprimary signers syndromeGCgastric cancerRCCrenal cell carcinomaGCGglucagonRETRearranged during transfectionGLP-1glucagon-like peptide-1ROS1Proto-oncogene tyrosine-protein kinase 1GPRC5DG protein-coupled receptor class C group 5 member DSBCshare based compensationHER2Human epidermal growth factor receptor 2sqsquamousIGF-1Rinsulin-like growth factor-1 receptorT2Dtype 2 diabetesIL-23p19anti-interleukin 23 p19 subunitTEDthyroid eye diseaseIL-4RaInterleukin 4 receptorTKItyrosine kinase inhibitorIOimmune-oncologyTSLPThymic stromal lymphopoietinMCLMantle cell lymphomaXO1xanthine oxidase inhibitor",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4638df5393addbac",
      "text": "Source: BofA Global Research",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "60aa1123d920b320",
      "text": "We derive our PO of HK\\$106.9 from a DCF model, assuming a WACC of \\(9.6\\%\\) and a terminal growth rate of \\(4\\%\\) . The DCF is based on PD- 1, biosimilars, mazdutide and a few other drugs' commercial sales as well as revenue estimate of key pipeline assets including IBI363 and others.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "405801742a130874",
      "text": "Downside risks: commercialization for PD- 1 and biosimilars below expectation, clinical development setback for late stage assets, and pricing pressure from NRDL's inclusion of competitors' products.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3f5d21075be86fbc",
      "text": "Upside risk: faster- than- expected sales growth of drugs included in NRDL.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "30b4c40df7a11ea7",
      "text": "APR-Healthcare Coverage Cluster",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "41737d46d840d33a",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystKyowa KirinKYKOF4151 JPKoichi MareganoMedleyXEQNF4480 JPRitsuo WatanabeMindrayXDVWF300760 CHSandra SunNxera PharmaSOLTF4565 JPKoichi MareganoOtsuka HDOTSKF4578 JPKoichi MareganoOtsuka HDOTSKYOTSKY USKoichi MareganoPharmaronPHBBF3759 HKDavid LiPolynovoCALZFPNV AULyanne HarrisonParam 9 HospitalXPNHFPR9 TBTeerapol Udomvej, CFAResMed IncRSMDFRMD AULyanne HarrisonResMed Inc.RMDRMD USLyanne HarrisonSanten Pharm.SNPHF4536 JPKoichi MareganoSawai Group HoldingsSWGHF4887 JPRitsuo WatanabeShanghai PharmaceuticalsSHPMF2607 HKDavid LiShanghai United ImagingXCAOF688271 CHSandra SunSHIMADZUSHMZF7701 JPRitsuo WatanabeShionogiSGIOF4507 JPKoichi MareganoShionogiSGIOYSGIOY USKoichi MareganoSino BiopharmSBMFF1177 HKDavid LiSinopharmSHTDF1099 HKDavid LiSonic Healthcare LimitedSKHCFSHL AULyanne HarrisonSysmexSSMXF6869 JPRitsuo WatanabeTakeda Pharm.TKPHF4502 JPKoichi MareganoTakeda Pharm.TAKTAK USKoichi MareganoTerumoTRUMF4543 JPRitsuo WatanabeTigerMedHTMDF3347 HKDavid LiWuxi ApptecWUXIF2359 HKDavid LiWuxi ApptecXLUHF603259 CHDavid LiYunnan BaiyaoYBAIF000538 CHSandra SunZhifeiXCHOF300122 CHDavid Li",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f668662cff2591be",
      "text": "AlkemXAMLFALKEM INNeha ManpuriaAsahi IntecAHICF7747 JPRitsuo WatanabeAstellas PharmaALPMF4503 JPKoichi MareganoAstellas PharmaALPMYALPMY USKoichi MareganoBangkok Dusit Medical ServicesBDMSFBDMS TBTeerapol Udomvej, CFAChugai Pharm.CHGCF4519 JPKoichi MareganoCochlear LimitedCHEOFCOH AULyanne HarrisonEBOS Group LimitedEBOSFEBO NZLyanne HarrisonEBOS Group LimitedXEBOFEBO AULyanne HarrisonEverest MedicineXMLKF1952 HKDavid LiFisher &amp;amp; Paykel HealthcareXPAXFFPH AULyanne HarrisonFisher &amp;amp; Paykel HealthcareFSPKFFPH NZLyanne HarrisonFujifilm HoldingsFUJIF4901 JPRitsuo WatanabeFUJIFILM HoldingsFUJIFFUJIF USRitsuo WatanabeKelun-BiotechXSKBF6990 HKDavid LiLupinXEFSFLPC INNeha ManpuriaM3MTHRF2413 JPRitsuo WatanabeMax HealthcareXMHIFMAXHEALT INNeha ManpuriaNew Industries Biomedical EngineeringXSNQF300832 CHSandra SunOlympus Corp.OCPNF7733 JPRitsuo WatanabeRamsay Health Care LimitedRMSYFRHC AULyanne HarrisonTopchoice MedicalXZDXF600763 CHEthan CuiTorrent PharmaTOPHFTRP INNeha ManpuriaWuXi BiologicsWXIBF2269 HKDavid LiZai LabZLABZLAB USDavid LiZai LabXCDZF9688 HKDavid LiZydus LifesciencesXMQLFZYDUSLIF INNeha Manpuria",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b95e9a9a3455decd",
      "text": "Ain HoldingsAINPF9627 JPRitsuo WatanabeAsymchem LaboratoriesXALPF002821 CHDavid LiAutobio Diagnostics Co LtdXQDXF603658 CHSandra SunBaiyunshanXOUFF600332 CHSandra SunBeijing Wantai Biological PharmacyXBHIIF603392 CHDavid Li",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "76407af4104ec0db",
      "text": "APR-Healthcare Coverage Cluster",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "d12564b10f8fbe89",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystCiplaXCLAFCIPLA INNeha ManpuriaCSPC PharmaceuticalCHJTF1093 HKEthan CuiEisaiESALF4523 JPKoichi MameganoFrontageFGHQF1521 HKDavid LiHelalus LimitedPHCRFHLS AULyanne HarrisonHengrui MedicineXMOKF600276 CHDavid LiJoinn LabXQT5F6127 HKDavid LiJoinn LabJOLCF603127 CHDavid LiMankind PharmaXDXZFMANKIND INNeha ManpuriaMedipal HoldingsMEPDF7459 JPRitsuo WatanabeOno Pharm.OPHLF4528 JPKoichi MameganoOvtekXOCKF300595 CHDavid LiPharmaronXLYGF300759 CHDavid LiPHC HoldingsPHCCF6523 JPRitsuo WatanabePien Tze HuangXUVHF600436 CHSandra SunShanghai PharmaceuticalsXKCRF601607 CHDavid LiSMSSMSZF2175 JPRitsuo WatanabeSun PharmaXPUCFSUNP INNeha ManpuriaTigerMedXHTHF300347 CHDavid LiYifeng PharmacyXYHCF603939 CHEthan CuiRSTRMicroPortMCRPF853 HKSandra SunTRYTXHXTF9164 JPRitsuo Watanabe",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "6cb00f63bc4f1b33",
      "text": "Business PerformanceNumeratorReturn On Capital EmployedNOPAT = (EBIT + Interest Income) × (1 – Tax Rate) + Goodwill AmortizationReturn On EquityNet IncomeOperating MarginOperating ProfitEarnings GrowthExpected 5 Year CAGR From Latest ActualFree Cash FlowCash Flow From Operations – Total CapexQuality of EarningsNumeratorCash Realization RatioCash Flow From OperationsAsset Replacement RatioCapexTax RateTax ChargeNet Debt-To-Equity RatioNet Debt = Total Debt – Cash &amp;amp; EquivalentsInterest CoverEBITValuation ToolkitNumeratorPrice / Earnings RatioCurrent Share PricePrice / Book ValueCurrent Share PriceDividend YieldAnnualised Declared Cash DividendFree Cash Flow YieldCash Flow From Operations – Total CapexEnterprise Value / SalesEV = Current Share Price × Current Shares + Minority Equity + Net Debt + Other LT LiabilitiesEV / EBITDAEnterprise Value",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "3afa52e67cce5ab2",
      "text": "i  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i  i  i  i  i  i  i  i  i  a  i  i  i  i  i  i  i  i  i  i  ii  i",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "63cca86bf93c6242",
      "text": "expenses from the issuer for such visits.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7fed131fcf8e0312",
      "text": "p  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  s  t  t  t  t  t  t  t  t  t  t  e  t  t",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "89798cdc5bdd1a25",
      "text": "basis for taxation may change.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "0e2423c1085bc952",
      "text": "h t t t t t t t t t t t t t t t t t t t t  t t t t t t t t t t t t t t t t t t t",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "000534b2df792509",
      "text": "BofA t  t t t t t t t t t t t t t t t t t t t t",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "be87945df6702af2",
      "text": "e t t t t t t t t t t t t t t t t t t t t",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8ece40ee5651cbae",
      "text": "BofA t t t t t t t t t t t t t t t t t t t t",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "61c782a50f0eb161",
      "text": "BofA t t t t t t t t t t t t t t t t t t t t",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d08e792f90529c51",
      "text": "Copyright and General Information:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4d0a6cc526f1b120",
      "text": "Copyright 2025 Bank of America Corporation. All rights reserved. iQdatabase is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. This document and its content is provided solely for informational purposes and cannot be used for training or developing artificial intelligence (AI) models or as an input in any AI application (collectively, an AI tool). Any attempt to utilize this document or any of its content in connection with an AI tool without explicit written permission from BofA Global Research is strictly prohibited. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly- available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "566911c54cff6cc3",
      "text": "Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co- defendants or co- plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f18474ec52617d13",
      "text": "This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofA's any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "0d2cec99795f2cdb",
      "text": "Any information relating to sustainability in this material is limited as discussed herein and is not intended to provide a comprehensive view on any sustainability claim with respect to any issuer or security.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "74a26307816130a3",
      "text": "Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "a5daa13e5101f90c",
      "text": "The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third- party websites. BofA Securities is not responsible for the content of any third- party website or any linked content contained in a third- party website. Content contained on such third- party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third- party website is at your own risk, and you should always review the terms and privacy policies at third- party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b81a1aaeb349351b",
      "text": "All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities are not obligated to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "6baba78f8bd890d7",
      "text": "Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy- related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "282ce4edcd5eecff",
      "text": "Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d8a0dea3fd8e386d",
      "text": "In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofA or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "27656d4a07fe5f9b",
      "text": "Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.",
      "page": 11,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "420cab4b39be6d6a",
      "name": "Adjusted Peak",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4898d0cf4ba8822a",
      "name": "Admin Expense",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "645f128997f142a3",
      "name": "Ain Holdings",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0932cb8d2b0b0ac7",
      "name": "America Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "517917b86efb07cf",
      "name": "Analyst Certification",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "838ea06ba425dee0",
      "name": "Annualised Declared",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cb358c677450e407",
      "name": "Asahi Intec",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "687cd03d96e468d6",
      "name": "Asset Replacement",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "88e7c22574311b3f",
      "name": "Astellas Pharma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d7ca112168434181",
      "name": "Asymchem Laboratories",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b681ac93ea9ea0b6",
      "name": "Autobio Diagnostics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3206071e540e388b",
      "name": "Autobio Diagnostics Co Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c509a51f8c52c423",
      "name": "Average Daily",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7f710f87608ca90d",
      "name": "Average Fully",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6b3368b1825872cb",
      "name": "Bangkok Dusit",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fdcfb87823fd5cca",
      "name": "Bank of America Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "27c290df29b6d433",
      "name": "Basic EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "83225c63e686faf6",
      "name": "Beijing Wantai",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c6b6c848afd6c7d8",
      "name": "Biological Pharmacy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "84cabe7d46a70133",
      "name": "Biomedical Engineering",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "TISLELIZUMAB",
            "unit": "%",
            "values": [
              26.3,
              28.6,
              29.0,
              28.4,
              28.5,
              27.5,
              28.1,
              29.4,
              30.2,
              30.5,
              30.6,
              29.2,
              28.8
            ]
          },
          {
            "name": "SINTILIMAB",
            "unit": "%",
            "values": [
              25.0,
              21.5,
              22.9,
              24.5,
              24.3,
              25.3,
              26.2,
              25.5,
              27.3,
              25.4,
              25.6,
              25.8,
              26.2
            ]
          },
          {
            "name": "PEMBROLIZUMAB",
            "unit": "%",
            "values": [
              13.2,
              14.8,
              13.6,
              12.6,
              13.1,
              12.5,
              11.7,
              12.0,
              10.2,
              12.1,
              11.5,
              12.0,
              11.6
            ]
          },
          {
            "name": "CAMRELIZUMAB",
            "unit": "%",
            "values": [
              13.9,
              9.7,
              9.8,
              10.8,
              11.1,
              11.0,
              10.9,
              11.0,
              10.4,
              9.8,
              10.0,
              11.0,
              10.7
            ]
          },
          {
            "name": "TORIPALIMAB",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "ATEZOLIZUMAB",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "NIVOLUMAB",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "SERPLULIMAB",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "9d604ffb0620987c",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": "2023年中国主要城市GDP排名",
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "上海",
              "北京",
              "深圳",
              "重庆",
              "广州",
              "苏州",
              "成都",
              "武汉",
              "杭州",
              "南京"
            ]
          },
          "y": {
            "unit": "万亿元",
            "range": {
              "min": 0,
              "max": 5
            }
          }
        },
        "series": [
          {
            "name": "GDP",
            "unit": "万亿元",
            "values": [
              4.72,
              4.38,
              3.46,
              3.01,
              3.04,
              2.46,
              2.23,
              2.0,
              2.0,
              1.75
            ]
          }
        ],
        "figure_id": "f0b95da049be2701",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "QILU PHARMACEUTICA",
            "unit": "%",
            "values": [
              47.4,
              47.3,
              43.8,
              44.4,
              44.9,
              42.9,
              41.5,
              40.3,
              41.6,
              40.4,
              40.4,
              39.9,
              39.2
            ]
          },
          {
            "name": "INNOVENT BIOLOGICS",
            "unit": "%",
            "values": [
              20.4,
              18.7,
              20.3,
              20.7,
              20.9,
              22.6,
              20.1,
              19.4,
              21.3,
              20.1,
              21.5,
              21.3,
              22.9
            ]
          },
          {
            "name": "ROCHE",
            "unit": "%",
            "values": [
              14.8,
              17.6,
              18.0,
              17.0,
              16.6,
              15.8,
              18.2,
              18.4,
              17.5,
              18.4,
              16.0,
              16.4,
              14.5
            ]
          },
          {
            "name": "JIANGSU HENGRUI",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "C.T-TIANQING GP.",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "TOT BIOPHARM",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "BEIGENE",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "SD.BOAN BIOTECH",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "HENLIUS BIOTECH",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "ZJ.BETA PHARMCEUTI",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "SINOCELLTECH LTD",
            "unit": "%",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "257c0c149542d0e6",
        "provenance": {
          "page": 6
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "b7cd86e37a039bd9",
        "value": 0.493,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "thanks to enhanced efficiency, S&M expense was RMB2.4bn, accounting for \\(45.4\\%\\) product revenue (49.3% in 1H24). Overall, Innovent achieved a net profit of RMB834mn, vs net loss of RMB393mn in 1H24",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "61e17c7ff0f9bf0f",
        "value": 0.542,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>(0.058)</td><td>0.335</td><td>0.849</td><td>1.76</td></tr><tr><td>EPS Change (YoY)</td><td>54.2%</td><td>91.3%</td><td>NM</td><td>153.6%</td><td>107.3%</td></tr><tr><td>Consensus EPS (Visible",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a25698956293b7d0",
        "value": 0.9129999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8)</td><td>0.335</td><td>0.849</td><td>1.76</td></tr><tr><td>EPS Change (YoY)</td><td>54.2%</td><td>91.3%</td><td>NM</td><td>153.6%</td><td>107.3%</td></tr><tr><td>Consensus EPS (Visible Alpha)</td><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a8f2d21e671844f0",
        "value": 1.536,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.849</td><td>1.76</td></tr><tr><td>EPS Change (YoY)</td><td>54.2%</td><td>91.3%</td><td>NM</td><td>153.6%</td><td>107.3%</td></tr><tr><td>Consensus EPS (Visible Alpha)</td><td></td><td></td><td>0.39<",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "488bfba1e86ea637",
        "value": 1.073,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".76</td></tr><tr><td>EPS Change (YoY)</td><td>54.2%</td><td>91.3%</td><td>NM</td><td>153.6%</td><td>107.3%</td></tr><tr><td>Consensus EPS (Visible Alpha)</td><td></td><td></td><td>0.39</td><td>0.65</t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b9a40ebff95e671b",
        "value": -0.0118,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">389.13x</td><td>90.52x</td><td>51.63x</td><td>30.53x</td></tr><tr><td>Free Cash Flow Yield</td><td>-1.18%</td><td>-1.20%</td><td>0.239%</td><td>0.511%</td><td>1.46%</td></tr></table> \\\\* For full def",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e5feaa46f36a49ce",
        "value": -0.012,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>90.52x</td><td>51.63x</td><td>30.53x</td></tr><tr><td>Free Cash Flow Yield</td><td>-1.18%</td><td>-1.20%</td><td>0.239%</td><td>0.511%</td><td>1.46%</td></tr></table> \\\\* For full definition of Meth",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5bee60481f41da8e",
        "value": 0.0023899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>51.63x</td><td>30.53x</td></tr><tr><td>Free Cash Flow Yield</td><td>-1.18%</td><td>-1.20%</td><td>0.239%</td><td>0.511%</td><td>1.46%</td></tr></table> \\\\* For full definition of Method\\\\* measures,",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "71201c54a8ae870c",
        "value": 0.00511,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>30.53x</td></tr><tr><td>Free Cash Flow Yield</td><td>-1.18%</td><td>-1.20%</td><td>0.239%</td><td>0.511%</td><td>1.46%</td></tr></table> \\\\* For full definition of Method\\\\* measures, see page 9. >>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "836de0920bb08ad4",
        "value": 0.0146,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Free Cash Flow Yield</td><td>-1.18%</td><td>-1.20%</td><td>0.239%</td><td>0.511%</td><td>1.46%</td></tr></table> \\\\* For full definition of Method\\\\* measures, see page 9. >> Employed by a ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4e74a16c6d1f511c",
        "value": 0.828,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "KD</td></tr><tr><td>Average Daily Value (mn)</td><td>254.95 USD</td></tr><tr><td>Free Float</td><td>82.8%</td></tr><tr><td>BoFA Ticker / Exchange</td><td>IVBXF / HKG</td></tr><tr><td>Bloomberg / Reute",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "265250aba949f835",
        "value": 0.040999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>Bloomberg / Reuters</td><td>1801 HK / 1801 HK</td></tr><tr><td>ROE (2025E)</td><td>4.1%</td></tr><tr><td>Net Dbt to Equity (Dec-2024A)</td><td>-35.8%</td></tr></table> SBC: share base",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "714e9c209edb895a",
        "value": -0.358,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "HK</td></tr><tr><td>ROE (2025E)</td><td>4.1%</td></tr><tr><td>Net Dbt to Equity (Dec-2024A)</td><td>-35.8%</td></tr></table> SBC: share based compensation PoS: probability of success CVM: cardiovascul",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1568e235696ff8ea",
        "value": 106.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "# Innovent # Rapid growth with global expansion story; reiterate Buy and lift PO to HK\\$106.9 Reiterate Rating: BUY | PO: 106.90 HKD | Price: 90.65 HKD ## Robust revenue growth and achieved net",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "febb115bbc366d2c",
        "value": 106.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "hange, the adjusted net profit reached RMB1,213mn (net loss of RMB160mn in 1H24). ## Lift PO to HK\\$106.9 and reiterate Buy This week, we note US FDA has cleared the IND application to initiate a glob",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "27083bcbecf77ddd",
        "value": 106.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "CC to \\(9.6\\%\\) from \\(10\\%\\) . Driven by raised peak sales forecast, we lift DCF- derived PO to HK\\$106.9 (from HK\\$70.1) and reiterate Buy given its solid R&D capability and rich pipeline portfolio.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2fcecf0114f394e2",
        "value": 70.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "from \\(10\\%\\) . Driven by raised peak sales forecast, we lift DCF- derived PO to HK\\$106.9 (from HK\\$70.1) and reiterate Buy given its solid R&D capability and rich pipeline portfolio. ## Enriched pro",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "024ac5f4d0bde356",
        "value": 80.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "SYCUME (petrotrumumab). Moreover, it has licensed- out IB13009 (DLL3 ADC) to Roche and received US\\$80mn in upfront payments. Near- term catalysts for Innovent include, 1) new products approval: autoi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a7bee36e85cf7857",
        "value": 70.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "nges</td><td></td></tr><tr><td>(CNY)</td><td>Previous Current</td></tr><tr><td>Price Obj.</td><td>HK$70.10 HK$106.90</td></tr></table> <table><tr><td colspan=\"2\">Stock Data</td></tr><tr><td>Price</td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7f03dc121dacd2c8",
        "value": 106.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td></tr><tr><td>(CNY)</td><td>Previous Current</td></tr><tr><td>Price Obj.</td><td>HK$70.10 HK$106.90</td></tr></table> <table><tr><td colspan=\"2\">Stock Data</td></tr><tr><td>Price</td><td>90.65",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5cf44a2330ea59e4",
        "value": -0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e*</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>-5.6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a0d416ebc020c3d1",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>-5.6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "598a1199550eea2f",
        "value": 0.063,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>-5.6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2202a3d2ad178cf2",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td></tr><tr><td>Return On Capital Employed</td><td>-5.6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "387758a2a8f9779b",
        "value": 0.16899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Return On Capital Employed</td><td>-5.6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6f046aef576b955d",
        "value": -0.08800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".6%</td><td>0.5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "58d666ee3211dba8",
        "value": -0.006999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5%</td><td>6.3%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a464ab45413f3701",
        "value": 0.040999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>11.0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "65230462066a14a9",
        "value": 0.096,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>16.9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6e06105772f72628",
        "value": 0.174,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".9%</td></tr><tr><td>Return On Equity</td><td>-8.8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2629814ad8233c1c",
        "value": -0.163,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".8%</td><td>-0.7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a0f35313f2e78625",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7%</td><td>4.1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "16185735197992ff",
        "value": 0.105,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1%</td><td>9.6%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "9808c83812b81300",
        "value": 0.149,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>17.4%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1d2d67533e8ac9ab",
        "value": 0.196,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>Operating Margin</td><td>-16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1c844fe002af6ee8",
        "value": -0.132,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "16.3%</td><td>1.5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td>20.5%</td></tr><tr><td>iQmethod™ - Quality o",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "bb6095ba73f5eb17",
        "value": 0.036000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".5%</td><td>10.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td>20.5%</td></tr><tr><td>iQmethod™ - Quality of Earnings</td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f2de65ed3332f9d4",
        "value": 0.121,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.5%</td><td>14.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td>20.5%</td></tr><tr><td>iQmethod™ - Quality of Earnings</td><td></td><td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "03cbe175008b683a",
        "value": 0.161,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4.9%</td><td>19.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td>20.5%</td></tr><tr><td>iQmethod™ - Quality of Earnings</td><td></td><td></td><td></td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "e04a145e9b2d3fce",
        "value": 0.205,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9.6%</td></tr><tr><td>EBITDA Margin</td><td>-13.2%</td><td>3.6%</td><td>12.1%</td><td>16.1%</td><td>20.5%</td></tr><tr><td>iQmethod™ - Quality of Earnings</td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "9a7e698ae7da9432",
        "value": 0.105,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7x</td><td>1.4x</td><td>1.2x</td><td>1.2x</td><td>1.7x</td></tr><tr><td>Tax Rate (Reported)</td><td>10.5%</td><td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Rati",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3a47c58df422d9b8",
        "value": 0.433,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "x</td><td>1.2x</td><td>1.2x</td><td>1.7x</td></tr><tr><td>Tax Rate (Reported)</td><td>10.5%</td><td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "45ae41f411a63dfe",
        "value": 0.067,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1.2x</td><td>1.7x</td></tr><tr><td>Tax Rate (Reported)</td><td>10.5%</td><td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0db68e5822d5604b",
        "value": 0.091,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1.7x</td></tr><tr><td>Tax Rate (Reported)</td><td>10.5%</td><td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f1f26a57bad641c3",
        "value": 0.105,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Tax Rate (Reported)</td><td>10.5%</td><td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "20d6e0f510b6d6dd",
        "value": -0.521,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>43.3%</td><td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td>-37.9%</td><td>-42.9%</td></tr><tr><td>Interest Cover</",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "271d59e50fdd9980",
        "value": -0.358,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>6.7%</td><td>9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td>-37.9%</td><td>-42.9%</td></tr><tr><td>Interest Cover</td><td>-10.2x</",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f4bb1f87dd6e16f7",
        "value": -0.36700000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">9.1%</td><td>10.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td>-37.9%</td><td>-42.9%</td></tr><tr><td>Interest Cover</td><td>-10.2x</td><td>2.2x</td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d00a3d9a21ff36d7",
        "value": -0.379,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.5%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td>-37.9%</td><td>-42.9%</td></tr><tr><td>Interest Cover</td><td>-10.2x</td><td>2.2x</td><td>7.3x</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "4dee9f894a97d63a",
        "value": -0.429,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Net Debt-to-Equity Ratio</td><td>-52.1%</td><td>-35.8%</td><td>-36.7%</td><td>-37.9%</td><td>-42.9%</td></tr><tr><td>Interest Cover</td><td>-10.2x</td><td>2.2x</td><td>7.3x</td><td>9.2x</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "c2699ee2c50390a2",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e</td><td>12,100</td><td>15,988</td><td>21,250</td><td>11,905</td><td>15,753</td><td>21,007</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>COGS</td><td>-2,150</td><td>-2,898</td><td>-3,701</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fdbc92e0a915fb5d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2,100</td><td>15,988</td><td>21,250</td><td>11,905</td><td>15,753</td><td>21,007</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>COGS</td><td>-2,150</td><td>-2,898</td><td>-3,701</td><td>-2,220</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "db3e6660f29096c0",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>15,988</td><td>21,250</td><td>11,905</td><td>15,753</td><td>21,007</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>COGS</td><td>-2,150</td><td>-2,898</td><td>-3,701</td><td>-2,220</td><td>-2,947<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6e2a4e8f4edb7c81",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "S</td><td>-2,150</td><td>-2,898</td><td>-3,701</td><td>-2,220</td><td>-2,947</td><td>-3,661</td><td>-3%</td><td>-2%</td><td>1%</td></tr><tr><td>Gross profit</td><td>9,953</td><td>13,090</td><td>17,548",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1d46dddd692a95bd",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",150</td><td>-2,898</td><td>-3,701</td><td>-2,220</td><td>-2,947</td><td>-3,661</td><td>-3%</td><td>-2%</td><td>1%</td></tr><tr><td>Gross profit</td><td>9,953</td><td>13,090</td><td>17,548</td><td>9,6",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "07aa18a815bceef7",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-2,898</td><td>-3,701</td><td>-2,220</td><td>-2,947</td><td>-3,661</td><td>-3%</td><td>-2%</td><td>1%</td></tr><tr><td>Gross profit</td><td>9,953</td><td>13,090</td><td>17,548</td><td>9,685</td><td>1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9a265016254e2c2d",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "fit</td><td>9,953</td><td>13,090</td><td>17,548</td><td>9,685</td><td>12,806</td><td>17,347</td><td>3%</td><td>2%</td><td>1%</td></tr><tr><td>R&amp;amp;D expense</td><td>-3,358</td><td>-4,462</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fdab2ed952a7d1ed",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">9,953</td><td>13,090</td><td>17,548</td><td>9,685</td><td>12,806</td><td>17,347</td><td>3%</td><td>2%</td><td>1%</td></tr><tr><td>R&amp;amp;D expense</td><td>-3,358</td><td>-4,462</td><td>-2,917</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ad00e85a01db6fc9",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>13,090</td><td>17,548</td><td>9,685</td><td>12,806</td><td>17,347</td><td>3%</td><td>2%</td><td>1%</td></tr><tr><td>R&amp;amp;D expense</td><td>-3,358</td><td>-4,462</td><td>-2,917</td><td>-3,308<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "100d9e5f2719c3ca",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mp;amp;D expense</td><td>-3,358</td><td>-4,462</td><td>-2,917</td><td>-3,308</td><td>-4,412</td><td>2%</td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>SG&amp;amp;A expense</td><td>-7,715</td><td>-7,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2553c3a87ad74a8a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pense</td><td>-3,358</td><td>-4,462</td><td>-2,917</td><td>-3,308</td><td>-4,412</td><td>2%</td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>SG&amp;amp;A expense</td><td>-7,715</td><td>-7,355</td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4a34578791da9936",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-3,358</td><td>-4,462</td><td>-2,917</td><td>-3,308</td><td>-4,412</td><td>2%</td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>SG&amp;amp;A expense</td><td>-7,715</td><td>-7,355</td><td>-8,925</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f06269f61ef54c2f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-4,462</td><td>-2,917</td><td>-3,308</td><td>-4,412</td><td>2%</td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>SG&amp;amp;A expense</td><td>-7,715</td><td>-7,355</td><td>-8,925</td><td>-5,619",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a7bd351615bc78d0",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e</td><td>-7,715</td><td>-7,355</td><td>-8,925</td><td>-5,619</td><td>-7,246</td><td>-8,823</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Other income/expense</td><td>400</td><td>400</td><td>400</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "84a3b5e96ad5db3e",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7,715</td><td>-7,355</td><td>-8,925</td><td>-5,619</td><td>-7,246</td><td>-8,823</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Other income/expense</td><td>400</td><td>400</td><td>400</td><td>400<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "db9e1bff8c821d60",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-7,355</td><td>-8,925</td><td>-5,619</td><td>-7,246</td><td>-8,823</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Other income/expense</td><td>400</td><td>400</td><td>400</td><td>400</td><td>400",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4b891fccba87fa8b",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ting income</td><td>679</td><td>1,687</td><td>3,361</td><td>738</td><td>1,759</td><td>3,530</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Other income/expenses</td><td>121</td><td>160</td><td>2",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c7991d0940ae8161",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>679</td><td>1,687</td><td>3,361</td><td>738</td><td>1,759</td><td>3,530</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Other income/expenses</td><td>121</td><td>160</td><td>212</td><td>1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d5eb367010c502dd",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1,687</td><td>3,361</td><td>738</td><td>1,759</td><td>3,530</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Other income/expenses</td><td>121</td><td>160</td><td>212</td><td>119</td><td>1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "69fc9428ed09bbbc",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "her income/expenses</td><td>121</td><td>160</td><td>212</td><td>119</td><td>158</td><td>210</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Finance costs</td><td>-174</td><td>-259</td><td>-281</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c7e80cd01d316a5e",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "expenses</td><td>121</td><td>160</td><td>212</td><td>119</td><td>158</td><td>210</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Finance costs</td><td>-174</td><td>-259</td><td>-281</td><td>-174</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "eb5509ef199c3fd6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>121</td><td>160</td><td>212</td><td>119</td><td>158</td><td>210</td><td>2%</td><td>1%</td><td>1%</td></tr><tr><td>Finance costs</td><td>-174</td><td>-259</td><td>-281</td><td>-174</td><td>-259</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4a7635fe438223b9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Finance costs</td><td>-174</td><td>-259</td><td>-281</td><td>-174</td><td>-259</td><td>-281</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Profit Before Tax</td><td>626</td><td>1,588</td><td>3,292<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "710028e8cfeb1ea9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ts</td><td>-174</td><td>-259</td><td>-281</td><td>-174</td><td>-259</td><td>-281</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Profit Before Tax</td><td>626</td><td>1,588</td><td>3,292</td><td>683",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "66bb8bc6096d6ac9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-174</td><td>-259</td><td>-281</td><td>-174</td><td>-259</td><td>-281</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Profit Before Tax</td><td>626</td><td>1,588</td><td>3,292</td><td>683</td><td>1,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "57d0b5fd624b14cd",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Before Tax</td><td>626</td><td>1,588</td><td>3,292</td><td>683</td><td>1,657</td><td>3,459</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Tax expense</td><td>-81</td><td>-206</td><td>-428</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "936c4777146a8ec2",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>626</td><td>1,588</td><td>3,292</td><td>683</td><td>1,657</td><td>3,459</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Tax expense</td><td>-81</td><td>-206</td><td>-428</td><td>-89</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e8c138ceb74c22ff",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1,588</td><td>3,292</td><td>683</td><td>1,657</td><td>3,459</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Tax expense</td><td>-81</td><td>-206</td><td>-428</td><td>-89</td><td>-215</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d7da326c96913754",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Tax expense</td><td>-81</td><td>-206</td><td>-428</td><td>-89</td><td>-215</td><td>-450</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Net Income</td><td>545</td><td>1,382</td><td>2,864</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "969d5e75a88da519",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nse</td><td>-81</td><td>-206</td><td>-428</td><td>-89</td><td>-215</td><td>-450</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Net Income</td><td>545</td><td>1,382</td><td>2,864</td><td>595</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c1af917e21168db0",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-81</td><td>-206</td><td>-428</td><td>-89</td><td>-215</td><td>-450</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Net Income</td><td>545</td><td>1,382</td><td>2,864</td><td>595</td><td>1,442</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "992c4a7090341830",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Net Income</td><td>545</td><td>1,382</td><td>2,864</td><td>595</td><td>1,442</td><td>3,009</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Basic EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "04a869b2cdfec8bd",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>545</td><td>1,382</td><td>2,864</td><td>595</td><td>1,442</td><td>3,009</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Basic EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "16f404ed707453c6",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1,382</td><td>2,864</td><td>595</td><td>1,442</td><td>3,009</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Basic EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "005058a6715e93e2",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Basic EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Fully diluted EPS</td><td>0.33</td><td>0.85</td><td>1.7",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0e7414d0eb3eddcd",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "S</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Fully diluted EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2248101c2775d58c",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td>Fully diluted EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "69754cf8e69b75d0",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y diluted EPS</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0e7414d0eb3eddcd",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "S</td><td>0.33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(cha",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2248101c2775d58c",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "33</td><td>0.85</td><td>1.76</td><td>0.37</td><td>0.89</td><td>1.85</td><td>-8%</td><td>-4%</td><td>-5%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(changes in perc",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "52c20ac850f15306",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>(changes in percentage points)</td><td></td><td></td></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4b3c92dd06377c2e",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "anges in percentage points)</td><td></td><td></td></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8ba6d0082f71d538",
        "value": 0.83,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "centage points)</td><td></td><td></td></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;a",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f90f46e2a06c3374",
        "value": 0.81,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ts)</td><td></td><td></td></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1e804d21f40f763d",
        "value": 0.81,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense % of sales<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c7fc978fba57b536",
        "value": 0.83,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Gross margin (%)</td><td>82%</td><td>82%</td><td>83%</td><td>81%</td><td>81%</td><td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense % of sales</td><td>-25%",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "eb766f39368bc1dc",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>83%</td><td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense % of sales</td><td>-25%</td><td>-21%</td><td>-21%</td><td>-25%</td><td>-21%</td><td>-21%</td><td>0.0</td><td>0.0</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a4d72f5c9d55b6bd",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>0.8</td><td>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense % of sales</td><td>-25%</td><td>-21%</td><td>-21%</td><td>-25%</td><td>-21%</td><td>-21%</td><td>0.0</td><td>0.0</td><td>0.0</td></t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1628ef91b2e4cac4",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>0.6</td><td>0.0</td></tr><tr><td>R&amp;amp;D expense % of sales</td><td>-25%</td><td>-21%</td><td>-21%</td><td>-25%</td><td>-21%</td><td>-21%</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>SG&",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d60e7e159b2a14ff",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0.0</td></tr><tr><td>R&amp;amp;D expense % of sales</td><td>-25%</td><td>-21%</td><td>-21%</td><td>-25%</td><td>-21%</td><td>-21%</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>SG&amp;amp;A % o",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "92c3065fc3258ab2",
        "value": 0.531,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mple drug sales data, in Jun 2025, Innovent booked total sample sales of RMB549.8mn, representing a 53.1% YoY growth. Its key drugs sintilimab and bevacizumab posted robust growth of 66.5% and 42.8% Y",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2933d3edb58e4e16",
        "value": 0.665,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ", representing a 53.1% YoY growth. Its key drugs sintilimab and bevacizumab posted robust growth of 66.5% and 42.8% YoY in Jun. Also thanks to the inclusion of NRDL, its tafolecimab registered RMB21.7",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c832f0600ba1fcc6",
        "value": 0.428,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ting a 53.1% YoY growth. Its key drugs sintilimab and bevacizumab posted robust growth of 66.5% and 42.8% YoY in Jun. Also thanks to the inclusion of NRDL, its tafolecimab registered RMB21.7mn sample ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "992dc2832b3caef1",
        "value": 0.358,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5,compared with RMB1.6mn in Jun 2024. Overall, in 1H25, Innovent's sample drug sales data witnessed 35.8% YoY growth, largely in line with its announced product sales growth of 37.3% in 1H25. Exhibit ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d895661b357527c2",
        "value": 0.373,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "g sales data witnessed 35.8% YoY growth, largely in line with its announced product sales growth of 37.3% in 1H25. Exhibit 6: Innovent's Jun 2025 IQVIA monthly drug sales up 53.1% YoY, or 35.8% YoY in",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "548d085e300ce540",
        "value": 0.531,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "product sales growth of 37.3% in 1H25. Exhibit 6: Innovent's Jun 2025 IQVIA monthly drug sales up 53.1% YoY, or 35.8% YoY in 1H25 One of its key drugs, sintilimab booked RMB257.8mn sales in Jun-25, re",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b09051b8965ad3d4",
        "value": 0.358,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth of 37.3% in 1H25. Exhibit 6: Innovent's Jun 2025 IQVIA monthly drug sales up 53.1% YoY, or 35.8% YoY in 1H25 One of its key drugs, sintilimab booked RMB257.8mn sales in Jun-25, representing a 6",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d254e5305f0b2e49",
        "value": 0.665,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".8% YoY in 1H25 One of its key drugs, sintilimab booked RMB257.8mn sales in Jun-25, representing a 66.5% YoY increase. Other key drugs that we monitor posted YoY growth change range from -4.2% to +128",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ae10648c015aecf2",
        "value": -0.042,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "resenting a 66.5% YoY increase. Other key drugs that we monitor posted YoY growth change range from -4.2% to +1289.0% in Jun-25. <table><tr><td>RMB mn</td><td>Jun-25</td><td>May-25</td><td>Apr-25</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bf7afbeda8d5635c",
        "value": 12.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a 66.5% YoY increase. Other key drugs that we monitor posted YoY growth change range from -4.2% to +1289.0% in Jun-25. <table><tr><td>RMB mn</td><td>Jun-25</td><td>May-25</td><td>Apr-25</td><td>Mar-25",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "629eb9e76bac2866",
        "value": 0.665,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>223.2</td><td>182.9</td><td>225.8</td><td>186.7</td><td>172.2</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "950c48b5f923482c",
        "value": 0.138,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>182.9</td><td>225.8</td><td>186.7</td><td>172.2</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5912a8a756364ac9",
        "value": 0.313,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>225.8</td><td>186.7</td><td>172.2</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "595fea54bb789609",
        "value": 0.449,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>186.7</td><td>172.2</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b5abe958eddb315d",
        "value": 0.47600000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>172.2</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "722d2151ca903905",
        "value": 0.466,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a7d9d2f5a88e4dca",
        "value": 0.586,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>YoY</td><td>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e0b6f55d038e5807",
        "value": 0.5529999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>66.5%</td><td>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZUMAB</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a4c699e8a6e143ff",
        "value": 0.7190000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>13.8%</td><td>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZUMAB</td><td>176.7</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8065dfb74a9068ee",
        "value": 0.221,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>31.3%</td><td>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZUMAB</td><td>176.7</td><td>171.0</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b7d7146c1337a50c",
        "value": 0.159,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>44.9%</td><td>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZUMAB</td><td>176.7</td><td>171.0</td><td>171.4</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "73e9efe4962ffe59",
        "value": 0.162,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>47.6%</td><td>46.6%</td><td>58.6%</td><td>55.3%</td><td>71.9%</td><td>22.1%</td><td>15.9%</td><td>16.2%</td></tr><tr><td>BEVACIZUMAB</td><td>176.7</td><td>171.0</td><td>171.4</td><td>154.0</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2a9cc2e65bf19f52",
        "value": 0.428,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>145.0</td><td>147.3</td><td>174.7</td><td>153.1</td><td>143.1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "adc4e8d8c1079c5f",
        "value": 0.026000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>147.3</td><td>174.7</td><td>153.1</td><td>143.1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c95e66d5cbcb522d",
        "value": 0.36200000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>174.7</td><td>153.1</td><td>143.1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>5",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4d543622a6cc6bd7",
        "value": 0.513,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>153.1</td><td>143.1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>5",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c6d75db1cccfbbe6",
        "value": 0.32299999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>143.1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>6",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "55b642276144ea13",
        "value": 0.645,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td></tr><tr><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e4c857a3df6dff99",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>YoY</td><td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXI",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "47404e6b74d9a20a",
        "value": 0.239,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>42.8%</td><td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXIMAB</td><td>67",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d9ebc66d9849f799",
        "value": 1.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2.6%</td><td>36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXIMAB</td><td>67.1</td><td>65.",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ecf6ca5c3aac2acb",
        "value": 0.5760000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">36.2%</td><td>51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXIMAB</td><td>67.1</td><td>65.2</td><td>71.8<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b3cf4c5cff3bd8ad",
        "value": 0.546,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">51.3%</td><td>32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXIMAB</td><td>67.1</td><td>65.2</td><td>71.8</td><td>62.5</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ea3921884e22d576",
        "value": 0.622,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">32.3%</td><td>64.5%</td><td>11.0%</td><td>23.9%</td><td>106.0%</td><td>57.6%</td><td>54.6%</td><td>62.2%</td></tr><tr><td>RITUXIMAB</td><td>67.1</td><td>65.2</td><td>71.8</td><td>62.5</td><td>51.5</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "dd777d9fd28d7646",
        "value": 0.142,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">62.6</td><td>57.4</td><td>57.6</td><td>73.9</td><td>65.9</td><td>59.5</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b23ca9920909a763",
        "value": -0.032,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "57.4</td><td>57.6</td><td>73.9</td><td>65.9</td><td>59.5</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d2de5923624fcaaa",
        "value": 0.156,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7.6</td><td>73.9</td><td>65.9</td><td>59.5</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a09a7957af4093f7",
        "value": 0.132,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".9</td><td>65.9</td><td>59.5</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8d800ad0b53d6adf",
        "value": 0.154,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>59.5</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "fc38935851504611",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "75762ce897794e80",
        "value": 0.413,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>YoY</td><td>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLEC",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2bc8c9418e1fdb9b",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>14.2%</td><td>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLECIMAB</td><td>2",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7d6863f1184fb70c",
        "value": 0.489,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-3.2%</td><td>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLECIMAB</td><td>21.7</td><td>17",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "726a8acb5c227824",
        "value": 0.28300000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15.6%</td><td>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLECIMAB</td><td>21.7</td><td>17.1</td><td>11.",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "941f15125a22cb3e",
        "value": 0.397,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>13.2%</td><td>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLECIMAB</td><td>21.7</td><td>17.1</td><td>11.0</td><td>3.1<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3cef15e8d96bfa55",
        "value": 0.494,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15.4%</td><td>19.0%</td><td>41.3%</td><td>18.0%</td><td>48.9%</td><td>28.3%</td><td>39.7%</td><td>49.4%</td></tr><tr><td>TAFOLECIMAB</td><td>21.7</td><td>17.1</td><td>11.0</td><td>3.1</td><td>2.7</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "542e403ad8358766",
        "value": 12.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.5</td><td>1.9</td><td>1.6</td><td>1.5</td><td>1.5</td><td>1.4</td></tr><tr><td>YoY</td><td>1289.0%</td><td>1503.1%</td><td>1053.8%</td><td>165.0%</td><td>213.0%</td><td>277.5%</td><td>-23.4%<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c6411615be64f70a",
        "value": 15.030999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1.9</td><td>1.6</td><td>1.5</td><td>1.5</td><td>1.4</td></tr><tr><td>YoY</td><td>1289.0%</td><td>1503.1%</td><td>1053.8%</td><td>165.0%</td><td>213.0%</td><td>277.5%</td><td>-23.4%</td><td>3053.7%<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "beefae2404eefcd3",
        "value": 10.538,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".6</td><td>1.5</td><td>1.5</td><td>1.4</td></tr><tr><td>YoY</td><td>1289.0%</td><td>1503.1%</td><td>1053.8%</td><td>165.0%</td><td>213.0%</td><td>277.5%</td><td>-23.4%</td><td>3053.7%</td><td>189.0%</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cdc7f3f725f529e0",
        "value": 1.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.5</td><td>1.4</td></tr><tr><td>YoY</td><td>1289.0%</td><td>1503.1%</td><td>1053.8%</td><td>165.0%</td><td>213.0%</td><td>277.5%</td><td>-23.4%</td><td>3053.7%</td><td>189.0%</td><td>203.7%</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "729f383025ab0fcc",
        "value": 0.262,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ilimab is continuously gaining market share from Mar-25. Notably, its market share was up 0.4ppt to 26.2% in Jun-25 vs. May-25 in China PD-1/L-1 market China PD- 1/L- 1 competition landscape: BeOne's ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "94831eb0b45927cb",
        "value": 0.22899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "is continuously gaining market share from Mar-25. In particular, its market share was up 1.6ppt to 22.9% in Jun-25 vs. May-25 in China bevacizumab market China bevacizumab competition landscape: Qilu ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3b95453f0c139102",
        "value": 106.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "## Price objective basis & risk ## Innovent (IVBXF) We derive our PO of HK\\$106.9 from a DCF model, assuming a WACC of \\(9.6\\%\\) and a terminal growth rate of \\(4\\%\\) . The DCF is ba",
        "provenance": {
          "page": 6
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 3,
      "tables_count": 0,
      "numerical_data_count": 153,
      "passages_count": 86,
      "entities_count": 20
    }
  }
}